Oktay, Kutluk H.Turan, Volkan2023-07-292023-07-292023Oktay, K. H., & Turan, V. (2023). Ovarian stimulation and oocyte cryopreservation in females with cancer. Current Opinion in Oncology, 35(5), pp. 412-419. https://doi.org/10.1097/CCO.0000000000000977https://doi.org/10.1097/CCO.0000000000000977https://hdl.handle.net/20.500.13055/513Purpose of review: We reviewed the most recent developments including the safety and effectiveness data and success rates in individualized ovarian stimulation protocols for adult and postpubertal females with cancer. Recent findings: In women with breast cancer, aromatase inhibitor- and tamoxifen-supplemented stimulation protocols increase the margin of safety by limiting estrogen exposure. The outcomes of ovarian stimulation appear similar between cancer and noncancer populations, even with the recently developed random-start protocols, which allow initiation of ovarian stimulation anytime during the menstrual cycle. Based on lower anti-Mullerian hormone levels and primordial follicle density, carriers of BRCA pathogenic variants (BRCApv) have decreased ovarian reserve in comparison to women without those variants and may lose larger portion of their ovarian reserve post chemotherapy. Oocyte cryopreservation is also emerging as a suitable fertility preservation approach for selected postpubertal girls as young as 12 years of age. Summary: Individualized ovarian stimulation approaches combined with improvements in cryopreservation techniques increased the success and safety margin to preserve fertility with oocyte freezing. Women with BRCApv, on the other hand, may be at disadvantage as they have lower ovarian reserve and may lose larger portion of their ovarian reserve post chemotherapy compared to women who do not carry these variants.eninfo:eu-repo/semantics/closedAccessBRCA Pathogenic VariantsCancerCryopreservationFertility PreservationOocyte FreezingOvarian StimulationReview Article10.1097/CCO.0000000000000977355412419Q3WOS:0010444635000092-s2.0-85167476485PMID: 37498110Q2